CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful hard but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last several shares. The 1st CytoDyn post of mine, “CytoDyn: What In order to Do When It is Too Good In order to Be True?”, set out what follows prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire employment interview which I came away with a bad viewpoint of the business.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, although the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the technology as well as linked intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) and also the very first new drug application approval ($5 million), and also royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it’s this single treatments and a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic company with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications and multiple delivering presentations.

Can it all be smoke cigarettes and mirrors? That’s a question I have been asking myself from the very beginning of my interest in this particular organization. Judging with the multiples of a huge number of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am much from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Scroll to top